Neuropathic pain (NeP) is generally considered an intractable problem, which becomes compelling in clinical practice when caused by highly effective chemotherapeutics, such as in the treatment of cancer with oxaliplatin (OXA) and related drugs. In the present work we describe a structurally new compound, ADM_09, which proved to effectively revert OXA-induced NeP in vivo in rats without eliciting the commonly observed negative side-effects. ADM_09 does not modify normal behavior in rats, does not show any toxicity toward astrocyte cell cultures, nor any significant cardiotoxicity. Patch-clamp recordings demonstrated that ADM_09 is an effective antagonist of the nociceptive sensor channel TRPA1, which persistently blocks mouse as well as human variants of TRPA1. A dual-binding mode of action has been proposed for ADM_09, in which a synergic combination of calcium-mediated binding of the carnosine residue and disulphide-bridge-forming of the lipoic acid residue accounts for the observed persistent blocking activity toward the TRPA1 channel.

A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain / Nativi, Cristina; Gualdani, R; Dragoni, Elisa; DI CESARE MANNELLI, Lorenzo; Sostegni, S; Norcini, M; Gabrielli, G; LA MARCA, Giancarlo; Richichi, Barbara; Francesconi, Oscar; Moncelli, MARIA ROSA; Ghelardini, Carla; Roelens, Stefano. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - ELETTRONICO. - 3:(2013), pp. 1-10. [10.1038/srep02005]

A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain

NATIVI, CRISTINA;DRAGONI, ELISA;DI CESARE MANNELLI, LORENZO;LA MARCA, GIANCARLO;RICHICHI, BARBARA;FRANCESCONI, OSCAR;MONCELLI, MARIA ROSA;GHELARDINI, CARLA;ROELENS, STEFANO
2013

Abstract

Neuropathic pain (NeP) is generally considered an intractable problem, which becomes compelling in clinical practice when caused by highly effective chemotherapeutics, such as in the treatment of cancer with oxaliplatin (OXA) and related drugs. In the present work we describe a structurally new compound, ADM_09, which proved to effectively revert OXA-induced NeP in vivo in rats without eliciting the commonly observed negative side-effects. ADM_09 does not modify normal behavior in rats, does not show any toxicity toward astrocyte cell cultures, nor any significant cardiotoxicity. Patch-clamp recordings demonstrated that ADM_09 is an effective antagonist of the nociceptive sensor channel TRPA1, which persistently blocks mouse as well as human variants of TRPA1. A dual-binding mode of action has been proposed for ADM_09, in which a synergic combination of calcium-mediated binding of the carnosine residue and disulphide-bridge-forming of the lipoic acid residue accounts for the observed persistent blocking activity toward the TRPA1 channel.
2013
3
1
10
Nativi, Cristina; Gualdani, R; Dragoni, Elisa; DI CESARE MANNELLI, Lorenzo; Sostegni, S; Norcini, M; Gabrielli, G; LA MARCA, Giancarlo; Richichi, Barb...espandi
File in questo prodotto:
File Dimensione Formato  
srep02005.pdf

Accesso chiuso

Tipologia: Altro
Licenza: Open Access
Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/945765
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 61
  • ???jsp.display-item.citation.isi??? 59
social impact